Identification of a New HIV-1 Intersubtype Circulating Recombinant Form (CRF123_0107) in Hebei province, China

2022 ◽  
Author(s):  
Ying Xing ◽  
Lijing Wang ◽  
Yating Li ◽  
Yuling Wang ◽  
Leilei Han ◽  
...  
Keyword(s):  
Hebei Province ◽  
Recombinant Form ◽  
Hiv 1

Genome Sequence of a Novel HIV-1 Circulating Recombinant Form (CRF103_01B) Identified from Hebei Province, China

2020 ◽  
Vol 36 (3) ◽  
pp. 234-241 ◽  
Author(s):  
Jiajia Zhou ◽  
Xinli Lu ◽  
Yi Feng ◽  
Miaomiao Li ◽  
Yanhui Zhu ◽  
...  
Keyword(s):  
Genome Sequence ◽  
Hebei Province ◽  
Recombinant Form ◽  
Hiv 1

scholarly journals No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments

2021 ◽  
Author(s):  
Basma Abdi ◽  
Mouna Chebbi ◽  
Marc Wirden ◽  
Elisa Teyssou ◽  
Sophie Sayon ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Routine Care ◽  
Biological Data ◽  
Recombinant Form ◽  
Hiv Integrase ◽  
Resistance Mutations ◽  
Clinical Routine ◽  
Inhibitor Resistance ◽  
Hiv 1

Abstract Background Little is known about HIV-1 integrase inhibitor resistance in the CNS. Objectives This study aimed to evaluate integrase inhibitor resistance in CSF, as a marker of the CNS, and compare it with the resistance in plasma. Methods HIV integrase was sequenced both in plasma and CSF for 59 HIV-1 patients. The clinical and biological data were collected from clinical routine care. Results Among the 59 HIV-1 patients, 32 (54.2%) were under antiretroviral (ARV) treatment. The median (IQR) HIV-1 RNA in the plasma of viraemic patients was 5.32 (3.85–5.80) and 3.59 (2.16–4.50) log10 copies/mL versus 4.79 (3.56–5.25) and 3.80 (2.68–4.33) log10 copies/mL in the CSF of ARV-naive and ARV-treated patients, respectively. The patients were mainly infected with non-B subtypes (72.2%) with the most prevalent recombinant form being CRF02_AG (42.4%). The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively. Integrase inhibitor resistance mutations in CSF were similar to those in plasma, except for 1/59 patients. Conclusions This work shows similar integrase inhibitor resistance profiles in the CNS and plasma in a population of HIV-1 viraemic patients.

Identification of a Newly Characterized HIV-1 BG Intersubtype Circulating Recombinant Form in Galicia, Spain, Which Exhibits a Pseudotype-Like Virion Structure

2002 ◽  
Vol 29 (5) ◽  
pp. 536-543 ◽  
Author(s):  
Elena Delgado ◽  
Michael M. Thomson ◽  
María Luisa Villahermosa ◽  
María Sierra ◽  
Antonio Ocampo ◽  
...  
Keyword(s):  
Recombinant Form ◽  
Virion Structure ◽  
Hiv 1

The first third-generation HIV-1 circulating recombinant form (CRF114_0155) identified in central China

2021 ◽  
Author(s):  
Yang Li ◽  
Yan Zhang ◽  
Hongye Wang ◽  
Long Liu ◽  
Hui Chen ◽  
...  
Keyword(s):  
Central China ◽  
Recombinant Form ◽  
Third Generation ◽  
Hiv 1

Genetic Characterization of a Novel HIV-1 CRF07_BC/CRF55_01B Recombinant Form Identified in Jiangmen, China

2020 ◽  
Vol 36 (2) ◽  
pp. 134-137 ◽  
Author(s):  
Min Han ◽  
Shixing Tang ◽  
Zhiju Li ◽  
Xin Guan ◽  
Nancai Zheng ◽  
...  
Keyword(s):  
Genetic Characterization ◽  
Recombinant Form ◽  
Hiv 1

scholarly journals HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form

Retrovirology ◽  
2010 ◽  
Vol 7 (1) ◽  
pp. 82 ◽  
Author(s):  
Thushan I de Silva ◽  
Roxanne Turner ◽  
Stephane Hue ◽  
Roochi Trikha ◽  
Carla van Tienen ◽  
...  
Keyword(s):  
The Gambia ◽  
Recombinant Form ◽  
Hiv 1 ◽  
Subtype Distribution

Spatiotemporal and demographic history of the HIV-1 circulating recombinant form CRF31_BC in Brazil

2018 ◽  
Vol 61 ◽  
pp. 113-118
Author(s):  
Hegger M. Fritsch ◽  
Sabrina E.M. Almeida ◽  
Aguinaldo R. Pinto ◽  
Tiago Gräf
Keyword(s):  
Demographic History ◽  
Recombinant Form ◽  
History Of ◽  
Hiv 1

scholarly journals Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece

2016 ◽  
Vol 145 (2) ◽  
pp. 401-412 ◽  
Author(s):  
G. K. NIKOLOPOULOS ◽  
A. KATSOULIDOU ◽  
M. KANTZANOU ◽  
C. ROKKA ◽  
C. TSIARA ◽  
...  
Keyword(s):  
Optical Density ◽  
People Who Inject Drugs ◽  
Recombinant Form ◽  
Hiv Diagnosis ◽  
Hiv Rna ◽  
Avidity Assay ◽  
Window Period ◽  
Treatment Naïve ◽  
Hiv 1 ◽  
Similar Incidence

SUMMARYThis analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) ⩽1·5 corresponds to a recency window period of 130 days. The proportion true recent (PTR) and proportion false recent (PFR) were estimated in 28 seroconverters and in 366 samples collected >6 months after HIV diagnosis, respectively. The association between LAg ODn and HIV RNA level was evaluated in 232 persons. The PTR was 85·7%. The PFR was 20·8% but fell to 5·9% in samples from treatment-naive individuals with long-standing infection (>1 year), and to 0 in samples with the circulating recombinant form CRF35 AD. A LAg-based algorithm with a PFR of 3·3% estimated a similar incidence trend to that calculated by analyses based on HIV-1 seroconversions. In recently infected persons indicated by LAg, the median log10 HIV RNA level was high (5·30, interquartile range 4·56–5·90). LAg can help identify highly infectious HIV(+) individuals as it accurately identifies recent infections and is correlated with the HIV RNA level. It can also produce reliable estimates of HIV-1 incidence.

Sign in / Sign up

Export Citation Format

Share Document